Pharmaceutical care on dose optimization of irinotecan directed by gene polymorphism in the colorectal cancer patient
10.13699/j.cnki.1001-6821.2016.08.022
- VernacularTitle:依据基因多态性优化伊立替康对结肠癌治疗剂量的药学监护
- Author:
Xia-Lan ZHANG
1
;
Zhan WANG
;
Li-Feng HUANG
;
Yuan-Sheng ZANG
;
Wan-Sheng CHEN
Author Information
1. 上海长征医院 药材科
- Keywords:
colon cancer;
chemotherapy;
irinotecan;
gene polymor-phism;
adverse drug reaction;
pharmaceutical care
- From:
The Chinese Journal of Clinical Pharmacology
2016;32(8):740-741
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the dosing optimization of irinotecan according to the UGT1 A1*6/*28 genoptype.Methods Clinical phar-macists assisted clinicians to optimize the dosage of irinotecan for the patient with the wide -type of UGT1A1*6 and UGT1A1*28, and discovered and corrected the adverse drug reactions in time.Results and Conclusion Clinical pharmacists suggested increasing the dose of irino-tecan and clinicians accepted it.The patient successfully received the 6 cycles of chemotherapy.The initial dose of irinotecan increased from 280 mg to 440 mg.The progression free survival was 4.5 months.There was not obvious adverse drug reactions occurred during the chemotherapy.
